<DOC>
	<DOC>NCT00144612</DOC>
	<brief_summary>An open-label, extension, Phase III study to evaluate the long-term safety and efficacy of MRA in patients with sJIA who were participated in Studies MRA011JP or MRA316JP</brief_summary>
	<brief_title>Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Juvenile</mesh_term>
	<criteria>Inclusion criteria (MRA011JP patients) Of the patients who received the three infusions of MRA at the same dose in the main evaluation period in the previous study and are currently in the continued treatment period the patients in whom it is confirmed that the drug is effective and there are no problems with safety (MRA316JP patients) Patients who proceed to the blind period and in whom the last observations are done after study completion or withdrawal Patients who receive the three infusions in the openlabel period and do not meet the criteria for transition to the blind period Exclusion criteria Patients who were not enrolled by 3 months after completion of the previous study Patients who have been treated with infliximab or etanercept from completion of the previous study until the start of treatment in this study</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>